Spotlight on Internal Medicine

Credits: 0.75 CME
Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: The Importance of Continued Co-management in the Treatment of PsA
Eric Ruderman, MD
Penn State College of Medicine

Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: The Importance of Continued Co-management in the Treatment of PsA

Start

Provided By

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: October 6, 2017
Expires: October 6, 2018
45 minutes to complete

Target Audience

Rheumatologists, dermatologists, and allied health care professionals involved in the treatment of patients with psoriasis and PsA.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  • Discuss the complementary skills and experience that a dermatologist and rheumatologist can each bring to the care of a patient with PsA.
  • Describe effective methods of inter-specialty communication that facilitate co-management of psoriasis patients with PsA.
  • Discuss the efficacy and safety of currently approved medications for the treatment of PsA.
  • Describe guideline-recommended use of available agents for the treatment of patients with psoriasis and PsA.

Activity Description

Psoriatic arthritis (PsA) is a serious, inflammatory arthritis associated with psoriasis and multiple comorbidities that often requires collaborative care between dermatologists, rheumatologists, and primary care clinicians. This activity will examine specialty collaboration and guideline-recommended treatment.

Faculty

Eric M. Ruderman, MD
Professor of Medicine
Associate Chief, Clinical Affairs
Division of Rheumatology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Dr. Ruderman has disclosed the following:
Consultant/Advisor: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Novartis, Pfizer
Research Grant: Pfizer


Joseph F. Merola, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Co-Director, Center for Skin and Related Musculoskeletal Diseases
Departments of Dermatology and Medicine
Division of Rheumatology
Brigham and Women's Hospital
Boston, MA

Dr. Merola has disclosed the following:
Speakers Bureau: AbbVie
Consultant/Advisor: AbbVie, Amgen, Biogen, GSK, Janssen, Kiniksa, Lilly, Mallinckrodt, Momenta, Novartis, Pfizer, Samumed, Sanofi, Science 37, UCB


Conflict of Interest Policy/Disclosure Statement

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

  • Click "Start Program"
  • Take the pre-test
  • Review the activity
  • Take the post-test and score 80%
  • You are allowed a total of 3 attempts
  • Complete the evaluation
  • View, print, or save a CME certificate verifying your credit/participation in this activity

Statement of Commercial Support

This activity is supported by independent educational grants from Novartis and AbbVie.

Disclaimer Statement/Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Novartis; or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Contact Information for Questions About the Activity

MCM Education
17 Blacksmith Road
Suite 100
Newtown, PA 18940
info@cmecorner.com

Hardware/Software Requirements

Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Internal Medicine Presentations

1.00 CME
Postgraduate Institute for Medicine
Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 28, 2018
Expires: June 27, 2019
1 hour

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY

Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).


Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric Simpson, MC, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME / CE
American Heart Association
AHA Enduring Webinar: Heart Failure Guidelines and Evidence-Based Practice: Practical Tips in Heart Failure Management - Webinar 3

AHA Enduring Webinar: Heart Failure Guidelines and Evidence-Based Practice: Practical Tips in Heart Failure Management - Webinar 3

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and Nurses specific to treating patients with heart failure

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension + atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This webinar focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This multifaceted education initiative is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

10 minutes – Introduction
20 minutes – Case Study #1
20 minutes – Case Study #2
5 minutes – Case Study #3
5 minutes – Q & A

Presenters: Deborah Crabbe, MD, Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA, & Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA

Planning Committee

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern


Deborah Crabbe, MD – Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University


Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine


Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure


Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No Disclosures
Deborah Crabbe, MD – No Disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 - 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hour. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  • Register and view the course online.
  • View the content in its entirety.
  • Complete a post-test with a minimum score of 80%.
  • Complete a survey of your learning experience.
  • Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis.

Disclaimer Statement

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Fred Porta
Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: June 25, 2018
Expires: June 25, 2019
45 minutes to complete

Provided By


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and internal medicine physicians involved in the care of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify known phenotypes and endotypes that can inform the development of personalized treatment plans for patients with severe asthma
  • Describe clinical trial data on the efficacy and safety of new and emerging therapies for the treatment of severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this educational activity will provide clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

J. Mark FitzGerald, MD
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia


Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

J. Mark FitzGerald, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: Amgen, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi/Regeneron, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi/Regeneron, TEVA

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2018 through June 25, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

1.00 CME / CNE
American Heart Association
CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Crohn’s & Colitis Foundation of America
IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
1 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases
  • Apply principles of therapeutic management according to clinical symptoms, duration, and severity of disease

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from AbbVie Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME
Crohn’s & Colitis Foundation of America
IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
0.5 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Decide which medical treatment to use in acute IBD flares and for long-term disease management
  • Identify IBD characteristics for which surgery is indicated

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .05 continuing education units (CEUs), which are equal to 0.5 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 75% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from Salix Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.50 CME
Postgraduate Institute for Medicine
Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: May 1, 2018
Expires: June 17, 2019
1.5 hours to complete

Faculty

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland


Marc D. Cohen, MD
Marc D. Cohen, MD
Emeritus Professor of Medicine, Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology, National Jewish Health
Denver, Colorado


Jeffrey R. Curtis, MD
Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor
in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama at Birmingham
Birmingham, Alabama


Jointly provided by

Commercial Support Statement

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time.

Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225 or the Postgraduate Institute for Medicine at (720) 895-5357.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This enduring activity is intended for rheumatologists, internal medicine physicians with a secondary specialty in rheumatology, physician assistants, and other clinicians who treat patients with rheumatic diseases.

Educational Needs

Clinical studies on patients with rheumatoid arthritis have consistently found that patients are more likely to respond and more likely to reach remission if they are treated with disease-modifying antirheumatic drugs (DMARDs) within 3 to 6 months of symptom onset. But studies of patients in clinical practice find that diagnosis is often delayed, and typically treatment begins a year or more after symptom onset. Clinicians need information on strategies to enable earlier treatment. Guidelines also recommend a treat-to-target approach with a goal of sustained remission. This approach requires ongoing monitoring and treatment changes to meet patient needs. New medications have been approved recently, adding to the rheumatologist’s armamentarium for treating rheumatoid arthritis.

Learning Objectives

At the conclusion of this program, participants should be better able to:

  • Design appropriate strategies to increase the timeliness of rheumatoid arthritis diagnosis and subsequent linkage to evidence-based care
  • Design appropriate strategies to relieve articular and systemic symptoms of rheumatoid arthritis
  • Design strategies for using the most appropriate therapies based on the safety and efficacy data of the emerging classes of therapies for rheumatoid arthritis, including anti-interleukin (IL)-6/IL-6R agents, tumor necrosis factor (TNF) inhibitors, and other biologic disease-modifying antirheumatic drugs (DMARDs)
  • Design treatment strategies for rheumatoid arthritis that take into consideration recommendations from current guidelines and emerging data from clinical trials
  • Describe the data presented at national and global scientific conferences that may help clinicians achieve the treatment goals for rheumatoid arthritis

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Marc D. Cohen, MD, has nothing to disclose.

Jeffrey R. Curtis, MD, Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, and UCB. Grant/Research Support: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Roche/Genentech, Pfizer, and UCB.

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci, Consultant: AbbVie, Galapagos, Lilly, and Pfizer. Grant/Research Support: Bristol-Myers Squibb, Janssen, Pfizer, and UCB.

The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Global Academy for Medical Education Staff: Mike LoPresti; Shirley V. Jones, MBA; and Margaret McLauglin, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Postgraduate Institute for Medicine: planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME
Postgraduate Institute for Medicine
Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: March 27, 2018
Expires: March 27, 2019
0.75 hour to complete

Jointly Provided By

Target Audience

Dermatology clinicians who manage patients with moderate-to-severe atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with atopic dermatitis that reflect evidence-based guidelines, use of new therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Address quality-of-life issues and psychosocial comorbidities in managing patients with atopic dermatitis
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Activity Description

Recent developments in the treatment of moderate-to-severe atopic dermatitis (AD) have changed the way in which we are able to manage the disease. This interactive case-based educational program allows you to meet 3 patients in an AD clinic, make management decisions, compare your responses with those of your peers, and learn from the experts about best management approaches.

Faculty

Mark Lebwohl, MD (Chair)
Kimberly and Eric J. Waldman Professor of Dermatology
Icahn School of Medicine at Mount Sinai
Chairman, Kimberly and Eric J. Waldman Department of Dermatology
Mount Sinai Health System
New York, NY


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY


David M. Pariser, MD, FACP, FAAD
Professor of Dermatology
Eastern Virginia Medical School
Virginia Clinical Research
Pariser Dermatology Specialists
Norfolk, VA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Mark Lebwohl, MD, is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, Valeant, and ViDac; Allergan, Aqua Leo-pharma, and Promius (Consultant)
  • Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Theravance, and Vitae (Consultant)
  • David M. Pariser, MD, FACP, FAAD, has affiliations with Bickel Biotechnology, Biofrontera AG, Celegene, Dermira, DUSA Pharmaceuticals, LEO Pharmaceuticals, Novartis, Promius, Regeneron, Sanofi, TheraVida, and Valeant (Consultant); Pfizer (Advisory Board); Abbott Laboratories, Amgen, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant Sciences, Eli Lilly, LEO Pharmaceuticals, Merck, Novartis, Novo Nordisk, Ortho Dermatologics, Peplin, Photocure, Promius, Regeneron, Stiefel, and Valeant (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Misha Mutizwa, MD, has affiliations with Celgene (Consulting Fees).
  • Sharon Powell, has no affiliations with commercial interests to disclose.       

Postgraduate Institute for Medicine
The following PIM planners and managers: Judi Smelker-Mitchek, MBA, MSN, RN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians/DOs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Technical Support

For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Conversations™: Achieving Success in RA Assessment and Management

Clinical Conversations™: Achieving Success in RA Assessment and Management

Start

Jointly Provided By

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC contact hour
0.5 APRN contact hour
Released: February 27, 2018
Expires: February 27, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of RA and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with RA

Activity Description

This exciting interactive activity in RA features 2 patient cases, challenging questions related to the cases, and video vignettes of the real patients presented during the activity. You will have an opportunity to hear from our expert faculty and learn from the patients' perspectives. Effective management of RA requires appropriate treatment selection up front, regular disease activity monitoring, and patient engagement. New and novel treatment approaches will also be discussed.

Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, Pfizer, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); and Johnson & Johnson, Merck, and Pfizer (Ownership Interest).

  • Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1.0 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

1.00 CME
Vindico
Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: February 15, 2018
Expires: February 14, 2019
1 hour to complete

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Simulation-services provided by Syandus

Support Statement

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Activity Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA

Disclosure:
Royalty: SLACK Incorporated;
Consulting Fees: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB;
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB;
Research Grant (paid to institution): Janssen Orthobiotech;
Author Honoraria: McMahon Publishing, Up to Date;
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media.



Faculty

Meenakshi Bewtra, MD, PhD, MPH
Assistant Professor of Medicine and Epidemiology
Center for Clinical Epidemiology and Biostatistics
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure:
Contracted Research: GlaxoSmithKline, Takeda.



Nabeel Khan, MD
Assistant Professor of Clinical Medicine
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Director of Gastroenterology
Philadelphia VA Medical Center
Philadelphia, PA

No relevant financial relationships to disclose.


Reviewer

Ronald Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 15, 2018 to February 14, 2019.

How To Participate in this Activity and Obtain CME Credit

  • Read the target audience, learning objectives, and faculty disclosures.
  • Launch the simulation from the link provided on GastroCE.com on a PC, Mac, tablet, or plus-size phone.
  • Complete the pretest and launch the first simulation scenario. Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all scenario objectives and assessment components are complete. You can exit the simulation and it will save your progress so that you can return to finish at a later time.
  • As you successfully complete more scenarios (2 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.00 credits). Click or tap "Credit" to determine your CE credit status and receive credit. Upon successful completion of the evaluation, you will receive a certificate of credit immediately via the browser.

Overview

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Improvement in the care of patients with IBD is needed, as evidenced by a recent study of insurance claims that showed approximately 80% of 32,883 patients with IBD received suboptimal therapy. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies.

To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD to avoid disease flares, prevent structural damage and disability, as well as restore quality of life. In this virtual IBD patient management simulator, an authentic in-office setting with patient interaction will be presented. This simulation will allow authentic practice in the management of a patient with IBD, including determining the appropriate therapy for IBD based on the type and severity.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with IBD.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Analyze endoscopic and histologic findings that are characteristic of specific types of inflammatory bowel disease.
  • Apply the safety and efficacy of conventional and new treatments when determining the appropriate therapy for inflammatory bowel disease, based upon type and severity.
  • Incorporate therapeutic drug monitoring, stool markers, and the assessment of mucosal healing in monitoring inflammatory bowel disease as well as in response to treatment, to better predict exacerbations.

Copyright Statement

This CME simulation activity is licensed to Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Copyright © 2018 Syandus Inc and Vindico Medical Education. All rights reserved. No part of this simulation activity may be reproduced without written permission from Vindico Medical Education and Syandus Inc. The material presented in this Vindico Medical Education continuing medical education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Syandus Inc. Neither Vindico Medical Education, Synadus Inc, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages